GSK expands AI drug discovery collaboration with Chai Discovery
GSK will gain access to Chai's platform, including its protein folding and design models, following a successful laboratory evaluation. The expansion was announced on 12 October.
Who is affected and how
- pharmaceuticals
- The expansion after the laboratory evaluation signals that protein design models may enter the research workflow.
- health IT
- Integrating the models into research data environments creates new technical requirements.
Sources
- Chai Discovery and GSK Expand AI Drug Discovery Collaboration Following Successful Laboratory Evaluationhlth.com · Oct 12, 2026
- Chai Discovery lands GSK deal after successful AI binder testsallsci.com · Oct 12, 2026
- AstraZeneca signs AI drug discovery deal with insitroquartz · Oct 15, 2026
- AstraZeneca Signs AI Drug-Discovery Deal Worth Up to $1.5 Billion. Only $40 Million Is Guaranteedyahoo finance · Oct 15, 2026
- AstraZeneca, Insitro strike AI drug discovery dealfox business · Oct 15, 2026
- AstraZeneca and Insitro Ink $1.86 Billion AI Drug Discovery Dealbloomberg · Oct 15, 2026
- AstraZeneca inks AI drug discovery deal with insitro (AZN:NYSE)seeking alpha · Oct 15, 2026
- AstraZeneca And insitro Enter AI Drug Discovery Collaboration Worth Up To Approximately $1.5 Billionpulse 2.0 · Oct 15, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.